Key Insights
- Merck, AstraZeneca, Lilly, and Sanofi put over £1.5 billion in UK pharma projects on pause, signaling policy-driven headwinds.
- UK’s drug pricing and rebate policies seen as “punitive and uncompetitive,” pushing R&D focus towards the US and Europe.
- Industry leaders stress that tangible reforms could restore the UK’s position as a global hub for biopharma innovation.
Merck Triggers Domino Effect with £1B Withdrawal
Merck’s decision to abandon its £1-billion London R&D facility has rippled across the industry, with AstraZeneca pausing a £200-million Cambridge site investment and shelving its £450-million vaccine plant in Liverpool. Lilly and Sanofi are similarly reassessing commitments, raising questions about the UK’s long-term attractiveness for pharma R&D.
AstraZeneca’s Bold Recalibration
CEO Pascal Soriot has openly criticized the UK’s undervaluation of innovative medicines. After shelving £650 million in projects, AstraZeneca is leaning toward US expansion, with a $50 billion investment pledge and even hinting at shifting its stock listing across the Atlantic—a move that would dramatically alter the UK’s life sciences landscape.
Lilly’s Gateway Labs on Hold
Lilly’s much-anticipated £279 million Gateway Labs project—designed to nurture early-stage biotech innovators—now faces uncertainty. Company executives cite the need for clearer UK policy direction before finalizing investment, underlining how regulatory uncertainty directly curtails innovation ecosystems.
Sanofi Calls for Tangible Change
While not tied to a specific cancelled project, Sanofi has paused fresh UK commitments. The company stresses the need for “tangible improvements” in the commercial environment, with executives warning that the UK has become too costly to operate and challenging to sell medicines, compared to global peers.
By
